Drug Trial Radar · NCT06788990
FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC
Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
650
Planned (sponsor's estimate)
Start
Jan 28, 2025
Primary completion
Apr 2028
Study completion Jul 2029
Sponsor
- Lead sponsor
- Bicara TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Jan 23, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Ficerafusp alfa is directed against two targets, Epidermal Growth Factor Receptor (EGFR) and Transforming Growth Factor beta (TGF-β). This study intends to evaluate the safety and efficacy of ficerafusp alfa in combination with pembrolizumab versus placebo with pembrolizumab in 1L PD-L1-positive, recurrent or metastatic Head and Neck Squamous Cell Carcinoma (HNSCC).
Conditions
- Metastatic Head and Neck Squamous Cell Carcinoma
- Recurrent Head and Neck Squamous Cell Carcinoma
Interventions
Ficerafusp alfaDrug
Investigational
Pembrolizumab (KEYTRUDA®)Drug
Immunotherapy agent used in combination with investigational agent
PlaceboDrug
Placebo Control
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 2 - Incidence and severity of TEAEs, treatment-treatment emergent SAEs TEAEs leading to dose interruption, dose reduction, or permanent discontinuation.Time frame: Up to 30 days post end of treatment for TEAEs (90 days for SAEs).
- Phase 2 - Objective Response Rate (ORR) per RECIST 1.1 by blinded independent central review (BICR)Time frame: Approximately 1 year.
- Phase 3 - Objective Response Rate (ORR) per RECIST 1.1 by BICR.Time frame: Approximately 2 years.
- Phase 3 - Overall Survival (OS)Time frame: Approximately 3 years.
Locations
242 sites in 28 countries. Site status is shown where the registry gives one.
University of Alabama Hospital (Site # 0137)
Birmingham, Alabama · Recruiting
Mayo Clinic Hospital (Site #0147)
Phoenix, Arizona · Recruiting
UC San Diego Moores Cancer Center (Site #0107)
La Jolla, California · Recruiting
UCLA Department of Medicine - Hematology/Oncology (Site #0106)
Los Angeles, California · Recruiting
UC Davis (Site#0144)
Sacramento, California · Recruiting
University of California San Francisco (Site #0130)
San Francisco, California · Recruiting
Stanford Cancer Institute (Site #0150)
Stanford, California · Recruiting
Rocky Mountain Cancer Centers, LLP (Site #0122)
Aurora, Colorado · Recruiting
Rocky Mountain Regional VAMC (Site #0124)
Aurora, Colorado · Recruiting
University of Colorado Cancer Center (UCCC) - Anschutz Medical Campus (Site#0121)
Aurora, Colorado · Recruiting
ChristianaCare Helen F. Graham Cancer Center and Research Institute (Site # 127)
Newark, Delaware · Recruiting
Mayo Clinic Florida (Site #0148)
Jacksonville, Florida · Recruiting
Cancer Care Centers of Brevard (Site #0136)
Palm Bay, Florida · Recruiting
Moffit Cancer Center (Site #0105)
Tampa, Florida · Recruiting
Captain James A Lovell Federal Health Care Center-VA North Chicago (Site # 133)
Chicago, Illinois · Recruiting
Indiana University Simon Cancer Center (Site #0164)
Indianapolis, Indiana · Recruiting
University of Iowa Hospitals & Clinics (Site#0140)
Iowa City, Iowa · Recruiting
University of Kansas Medical Center Research Institute, Inc. (Site #0149)
Westwood, Kansas · Recruiting
University of Kentucky, Markey Cancer Center (Site # 109)
Lexington, Kentucky · Recruiting
Norton Cancer Institute (Site#0111)
Louisville, Kentucky · Recruiting
The University of Louisville, James Graham Brown Cancer Center (Site#0115)
Louisville, Kentucky · Recruiting
University of Maryland Medical Group (Site #0112)
Baltimore, Maryland · Recruiting
Massachusetts General Hospital (Site #0131)
Boston, Massachusetts · Recruiting
Dana-Farber Cancer Institute (Site#0101)
Boston, Massachusetts · Recruiting
University of Michigan (Site # 161)
Ann Arbor, Michigan · Recruiting
Minnesota Oncology Hematology, P.A. (Site #0156)
Maplewood, Minnesota · Recruiting
Mayo Clinic Cancer Center - Rochester (Site #0146)
Rochester, Minnesota · Recruiting
Washington University School of Medicine (Site #0114)
St Louis, Missouri · Recruiting
Hackensack Meridian Health (Site # 119)
Hackensack, New Jersey · Recruiting
Rutgers- Cancer Institute (Site #0145)
Newark, New Jersey · Recruiting
Mount Sinai (Site #0155)
New York, New York · Recruiting
Memorial Sloan Kettering Cancer Center (Site#0142)
New York, New York · Recruiting
Duke University Health System (Site#0118)
Durham, North Carolina · Recruiting
Mercy Hospital (Site#0154)
Canton, Ohio · Recruiting
University of Cincinnati Cancer Institute (Site#0117)
Cincinnati, Ohio · Recruiting
University Hospitals Seidman Cancer Center (Site #0151)
Cleveland, Ohio · Recruiting
Cleveland Clinic (Site #0108)
Cleveland, Ohio · Recruiting
Providence Portland Medical Center (Site #0113)
Portland, Oregon · Recruiting
UPMC Hillman Cancer Center (Site #0103)
Pittsburgh, Pennsylvania · Recruiting
VA Pittsburgh Healthcare System (Site #0123)
Pittsburgh, Pennsylvania · Recruiting
Showing 40 of 242 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.